Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

174 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effects of once-daily darunavir/ritonavir versus atazanavir/ritonavir on insulin sensitivity in HIV-infected persons over 48 weeks: results of an exploratory substudy of METABOLIK, a phase 4, randomized trial.
Overton ET, Tebas P, Coate B, Ryan R, Perniciaro A, Dayaram YK, De La Rosa G, Baugh BP. Overton ET, et al. Among authors: de la rosa g. HIV Clin Trials. 2016 Mar;17(2):72-7. doi: 10.1080/15284336.2016.1141468. HIV Clin Trials. 2016. PMID: 26917112 Free PMC article. Clinical Trial.
Darunavir outcomes study: comparative effectiveness of virologic suppression, regimen durability, and discontinuation reasons for three-class experienced patients at 48 weeks.
Willig JH, Aban I, Nevin CR, Ye J, Raper JL, McKinnel JA, Delaitsch LL, Mrus JM, De La Rosa GR, Mugavero MJ, Saag MS. Willig JH, et al. AIDS Res Hum Retroviruses. 2010 Dec;26(12):1279-85. doi: 10.1089/aid.2010.0059. Epub 2010 Oct 21. AIDS Res Hum Retroviruses. 2010. PMID: 20961276 Free PMC article.
Pharmacoeconomics of darunavir.
Fullerton DS, Smets E, De La Rosa G, Mrus JM. Fullerton DS, et al. Among authors: de la rosa g. Expert Rev Pharmacoecon Outcomes Res. 2011 Feb;11(1):27-39. doi: 10.1586/erp.10.88. Expert Rev Pharmacoecon Outcomes Res. 2011. PMID: 21351854 Review.
Why START? Reflections that led to the conduct of this large long-term strategic HIV trial.
INSIGHT Strategic Timing of AntiRetroviral Treatment (START) Study Group; Lundgren J, Babiker A, Gordin F, Emery S, Fätkenheuer G, Molina JM, Wood R, Neaton JD. INSIGHT Strategic Timing of AntiRetroviral Treatment (START) Study Group, et al. HIV Med. 2015 Apr;16 Suppl 1(0 1):1-9. doi: 10.1111/hiv.12227. HIV Med. 2015. PMID: 25711317 Free PMC article. No abstract available.
Development of diagnostic criteria for serious non-AIDS events in HIV clinical trials.
Lifson AR; INSIGHT Endpoint Review Committee Writing Group; Belloso WH, Davey RT, Duprez D, Gatell JM, Hoy JF, Krum EA, Nelson R, Pedersen C, Perez G, Price RW, Prineas RJ, Rhame FS, Sampson JH, Worley J, INSIGHT Study Group. Lifson AR, et al. HIV Clin Trials. 2010 Jul-Aug;11(4):205-19. doi: 10.1310/hct1104-205. HIV Clin Trials. 2010. PMID: 20974576 Free PMC article.
Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial.
Jacobson IM, Dore GJ, Foster GR, Fried MW, Radu M, Rafalsky VV, Moroz L, Craxi A, Peeters M, Lenz O, Ouwerkerk-Mahadevan S, De La Rosa G, Kalmeijer R, Scott J, Sinha R, Beumont-Mauviel M. Jacobson IM, et al. Among authors: de la rosa g. Lancet. 2014 Aug 2;384(9941):403-13. doi: 10.1016/S0140-6736(14)60494-3. Epub 2014 Jun 4. Lancet. 2014. PMID: 24907225 Free article. Clinical Trial.
174 results